Vical researches and develops biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Our active independent and partnered development programs include:
- Infectious disease vaccines for use in high-risk populations
- Infectious disease vaccines for general pediatric, adolescent and adult populations
- Gene-based delivery of angiogenic growth factors for treatment of cardiovascular diseases
Headquartered in San Diego, CA, Vical is independently pioneering the development of paradigm-changing DNA vaccines, and is partnering with such industry leaders as sanofi-aventis, Novartis, Astellas, AnGes, Merial and the NIH.